If you have been reading about cyclic heptapeptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-05-21. Numbers and descriptions here follow the published literature rather than marketing material.
Quality assessment of research-grade peptide rests mainly on reversed-phase high-performance liquid chromatography for purity and on mass spectrometry for identity confirmation. A single main peak above a stated threshold, commonly ninety-eight percent by peak area, is the usual release criterion applied by suppliers. Independent analyses commissioned by laboratories and consumer organisations have repeatedly reported discrepancies between label claims and measured content, including truncated sequences, residual trifluoroacetate, and lower-than-declared peptide mass. Those findings do not establish that every supplier is unreliable, but they indicate that purity figures printed on a vial are claims requiring verification rather than settled facts.
Regulatory treatment varies by jurisdiction and has changed over time. In several countries the peptide is handled as an unapproved prescription medicine, and import or sale for human use is restricted, while elsewhere it falls under poisons or controlled-substance schedules. Enforcement activity against online vendors has been reported in Australia, New Zealand, the United Kingdom and the United States. Scholarly writing discusses melanotan-2 chiefly as an experimental tool and as a case study in unregulated peptide supply, and its precise legal position in any given country should be checked against current national schedules.
Lyophilised melanotan-2 is comparatively robust when kept dry, cold and dark, and a desiccated powder stored at minus twenty degrees Celsius or below is generally expected to retain its chemical integrity for extended periods. In solution the peptide is far less stable, with degradation proceeding through oxidation of tryptophan and histidine residues, hydrolysis adjacent to the lactam bridge, and aggregation at higher concentrations. Repeated freeze-thaw cycling accelerates loss of the parent peak. Working aliquots are therefore prepared once, held cold, and used without letting the stock return to ambient temperature.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilised powder | Reconstitution is required before use in most assays |
| Solubility class | Freely soluble in water and acetonitrile; sparingly soluble in nonpolar solvents | Aqueous solutions may benefit from slight acidification |
| Typical storage temperature | -20 °C or lower, desiccated and protected from light | Short-term transport at 2-8 °C is common practice |
| Primary degradation routes | Oxidation, hydrolysis, aggregation | Tryptophan and histidine residues are the main oxidation targets |
| Quality marker | Chromatographic purity by peak area | Does not capture counter-ion content or residual solvents |
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Retention time supports identity, while the mass spectrum confirms the molecular weight of the intact peptide. Purity is frequently reported as a percentage of total peak area, a figure that depends on the wavelength, column and gradient used. Impurity profiling may also look for truncated sequences, oxidised forms and residual counterions. Amino acid analysis and peptide mapping provide orthogonal confirmation when required.
Regulatory status varies by jurisdiction, and the substance is frequently described as unapproved for therapeutic use. Some authorities classify it alongside prescription-only medicines or controlled categories, while others address it through general consumer protection rules. Analytical surveys have reported mismatches between label claims and measured content in products sold online, although the scope of such testing is limited. Whether these discrepancies are widespread remains an open question. Discussion in the literature therefore tends to combine chemistry, supply-chain observation and policy analysis.
The material is commonly handled as a lyophilized powder in sealed vials. The solid dissolves readily in water and in polar organic solvents, producing a clear solution after reconstitution. Light, heat and repeated freeze-thaw cycles are the concerns most often raised in handling guidance, because peptide bonds and the constrained ring can degrade. Working solutions are generally prepared fresh, and material left in solution is treated as less stable than the dry form. These properties shape how laboratories store and aliquot reference material.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Reversed-phase high-performance liquid chromatography is the routine method for purity assessment. Peptides absorb near 214 nm because of the peptide bond, and a gradient of acetonitrile in water separates the intact peptide from deletion sequences, oxidised products, and earlier-eluting fragments at neutral pH. Electrospray ionisation mass spectrometry provides an orthogonal check: the measured mass must agree with the theoretical value. Amino acid analysis and peptide mapping confirm structure but are used less often. Reference standards remain scarce because the peptide is not described in any pharmacopoeia.
Regulatory treatment varies by country. In the United States the peptide is not approved as a medicine, and products offered for human use may be treated as unapproved new drugs; some states also restrict sale. Australia, the United Kingdom, and European Union member states apply comparable restrictions to unapproved peptide products. Border agencies have seized shipments labelled as research chemicals. Classification may change over time, and the legal position for personal importation is not clearly settled in most published guidance.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
== Awards and honors == 1976–1981 - N.I.H. Research Career Development Award 1975, 1992 - Kaiser Permanente Award for Excellence in Teaching 1996–1997 - President, Biophysical Society 1997 - Distinguished Lecturer, Beckman Center, University of Illinois at Urbana-Champaign 1999 - Distinguished Service Award, Biophysical Society 2000 - Athalie Clarke Research Achievement Award, Outstanding Researcher, UCI College of Medicine 2001 - Fellow, Biophysical Society 2002 - César Milstein Plenary Lecture, XIVth International Biophysics Congress 2006 - Keynote Lecture, Gordon Research Conference on Biopolymers 2008 - Ph.D. honoris causa, Stockholm University 2009 - Avanti Award in Lipids, Biophysical Society 2009 - Bioengineering Distinguished Speaker, University of California at Riverside 2010 - Matrone Distinguished Lecture in Biochemistry, North Carolina State University 2010 - Cátedra de Investigación Científica, Autonomous University of San Luis Potosí 2010 - Frederic M. Richards Lecture, Yale 2011 - O'Malley Lectures in Chemical Biology, Boston College 2014 - Carl Brändén Award, The Protein Society 2016 - Fellow, Neutron Scattering Society of America 2018 - Fellow, American Association for the Advancement of Science 2019 - University of Kansas Newmark Award Lecture 2022 - UCI School of Medicine, Lifetime Research Achievement Award for Excellence in Basic Science research.
=== Discontinued === 1-Amino-5-bromouracil (ABU) – undefined mechanism of action [60] ABT-418 – nicotinic acetylcholine receptor agonist [61] ABT-436 – vasopressin V1B receptor antagonist [62] Adipiplon (NG-273) – GABAA receptor positive allosteric modulator and nonbenzodiazepine [63] Alnespirone (S-20499) – serotonin 5-HT1A receptor agonist [64] Alosetron (GR-68755; GR-68755C; Lotronex) – serotonin 5-HT3 receptor antagonist [65] Alpidem (Ananxyl; S-800342-001; SL-800342) – GABAA receptor positive allosteric modulator and nonbenzodiazepine/imidazopyridine [66] Alprazolam lingual spray – GABAA receptor positive allosteric modulator and benzodiazepine [67] AN-788 (IP-2018; NSD788) – serotonin–dopamine reuptake inhibitor (SDRI) [68] AP-521 – serotonin 5-HT1A receptor partial agonist [69] Aprepitant (Emend; L-754030; MK-0869; MK-869; ONO-7436) – neurokinin NK1 receptor antagonist [70] AVN-211 (CD-008-0173) – serotonin 5-HT6 receptor antagonist [71] AVN-397 – undefined mechanism of action [72] AZD-2327 – δ-opioid receptor (DOR) agonist [73] AZD-8129 (AR-A000002; AR-A2XX; AR-A2) – serotonin 5-HT1B receptor antagonist [74] Befloxatone (MD-370503) – reversible inhibitor of monoamine oxidase A (RIMA) [75] Blarcamesine (AE-37; ANA001; ANAVEX 2-73) – sigma σ1 receptor agonist, muscarinic acetylcholine M1 receptor agonist, and ionotropic glutamate NMDA receptor agonist [76] Bretazenil (RO-166028) – GABAA receptor positive allosteric modulator and benzodiazepine [77] Brofaromine (Brofaremine; CGP-11305A; Consonar; Consonev) – reversible inhibitor of monoamine oxidase A (RIMA) and serotonin reuptake inhibitor (SRI) [78] Buspirone transdermal (BuSpar Patch) – serotonin 5-HT1A receptor partial agonist and other actions [79] CGS-12066 – serotonin 5-HT1B receptor partial agonist and other actions [80] Coluracetam (BCI-540; MKC-231) – ionotropic glutamate AMPA receptor positive allosteric modulator, choline uptake and acetylcholine synthesis enhancer, and racetam [81] DAA-1097 – translocator protein (TSPO) agonist [82] Devazepide (Devacade; L-364718; MK-329) – Cholecystokinin A (CCKA) receptor antagonist [83] Dipraglurant (ADX-48621; mGluR5-NAM) – metabotropic glutamate mGlu5 receptor negative allosteric modulator [84] Eglumetad (eglumegad; LY-354740) – metabotropic glutamate mGlu2 and mGlu3 receptor agonist [85] Emapunil (AC-5216; XBD173) – translocator protein (TSPO) agonist [86] Emicerfont (GW-876008; GW876008) – corticotropin releasing factor CRF1 receptor antagonist [87] Enciprazine (D-3112; WY-48624) – serotonin 5-HT1A receptor agonist and α1-adrenergic receptor ligand [88] Eplivanserin (Ciltyri; Sliwens; SR-46349; SR-46349B; SR-46615A) – serotonin 5-HT2A receptor antagonist [89] Eptapirone (F-11440) – serotonin 5-HT1A receptor agonist [90] Esprolol ((S)-ACC-9369) – beta blocker (β-adrenergic receptor antagonist) (amoxolol prodrug) [91] Flesinoxan (DU-29373) – serotonin 5-HT1A receptor agonist [92] Gabapentin (CI-945; Gabapen; GOE-3450; Neurontin) – gabapentinoid (α2δ subunit-containing voltage-gated calcium channel ligand) [93] Girisopam (EGIS-5810; GYKI-51189) – GABAA receptor positive allosteric modulator and benzodiazepine [94] GT-2203 – histamine H3 receptor agonist [95] Guanfacine (Guanfacine Carrier Wave project; SPD-554) – α2-adrenergic receptor agonist [96] Ipsapirone (BAY-Q-7821; TVX-Q-7821) – serotonin 5-HT1A receptor partial agonist [97] Isamoltane (CGP-361A) – beta blocker (β-adrenergic receptor antagonist) and serotonin 5-HT1A and 5-HT1B receptor antagonist [98] Itasetron (DAU-6215; U-98079) – serotonin 5-HT3 receptor antagonist [99] ITI-333 – serotonin 5-HT2A receptor antagonist, dopamine D1 receptor antagonist, α1A-adrenergic receptor antagonist, and μ-opioid receptor (MOR) partial agonist [100] JNJ-19567470 (CRA-5626; R-317573) – corticotropin releasing factor CRF1 receptor antagonist [101] Levetiracetam (Keppra; L-059; SIB-S1; UCB-059; UCB-22059; UCB-L059) – synaptic vesicle glycoprotein 2A (SV2A) ligand [102] Lorazepam intranasal – GABAA receptor positive allosteric modulator and benzodiazepine [103] Mavoglurant (AFQ-056; STP-7) – metabotropic glutamate mGlu5 receptor antagonist [104] Midazolam intranasal (ITI-111; midazolam nasal spray; Nayzilam; USL-261) – GABAA receptor positive allosteric modulator and benzodiazepine [105] MK-0777 (L-830982; TPA-023) – GABAA receptor positive allosteric modulator and nonbenzodiazepine/triazolopyridazine [106] NBI-34041 (SB-723620) – corticotropin-releasing hormone (CRH) inhibitor [107] Nerisopam (EGIS-6775; GYKI-52322) – GABAA receptor positive allosteric modulator and benzodiazepine [108] Nivasorexant (ACT-539313; SORA) – orexin OX1 receptor antagonist [109] NS-11821 (NS11821) – GABAA receptor positive allosteric modulator and nonbenzodiazepine [110] Orvepitant (GW-823296; GW823296X) – neurokinin NK1 receptor antagonist [111] Osanetant (ACER-801; SR-142801; SR-142806) – neurokinin NK3 receptor antagonist [112] Panadiplon (FD-10571; FG-10571; NNC-140571; U-78875) – GABAA receptor positive allosteric modulator and nonbenzodiazepine/pyrazolopyrimidine [113] Pazinaclone (A-77000; DN-2327) – GABAA receptor positive allosteric modulator and nonbenzodiazepine/cyclopyrrolone [114] Pozanicline (A-87089.0; ABT-089) – nicotinic acetylcholine receptor agonist [115] Psilocybin (CYB-001; INT0052/2020) – non-selective serotonin receptor agonist and psychedelic hallucinogen [116] Research programme: depression and anxiety therapies - Roche/Vernalis – undefined mechanism of action [117] Research programme: GPCR modulators - Nxera Pharma – various actions [118] Research programme: monoamine oxidase A inhibitors - CeNeRx BioPharma – monoamine oxidase A (MAO-A) inhibitors [119] Ritanserin (R-55667) – serotonin 5-HT2 receptor antagonist and other actions [120] Robalzotan (AZD-7371; NAD-299) – serotonin 5-HT1A receptor antagonist [121] RS-127445 (MT-500) – serotonin 5-HT2B receptor antagonist [122] SAX-187 (WAY-181187) – serotonin 5-HT6 receptor agonist [123] Sergolexole (LY-281067) – serotonin 5-HT2 receptor antagonist [124] Siramesine (LU-28179) – sigma σ2 receptor agonist [125] SKL-PSY (FZ-016) – serotonin 5-HT1A receptor agonist [126] SSR-241586 (SSR241586) – neurokinin NK2 and NK3 receptor antagonist [127] SUN-8399 – serotonin 5-HT1A receptor agonist [128] Suriclone (RP-31264) – GABAA receptor positive allosteric modulator and nonbenzodiazepine/cyclopyrrolone [129] Talaglumetad (LY-544344) – metabotropic glutamate mGlu2 and mGlu3 receptor agonist (eglumetad prodrug) [130] Tiagabine (A-70569; CEP-6671; Gabitril; NO-050328; NO-328) – GABA transporter 1 (GAT-1) blocker and GABA reuptake inhibitor Troriluzole (BHV-4157; Dazluma; FC-4157; trigriluzole) – various actions (riluzole prodrug) [131] Vestipitant (GW-597599) – neurokinin NK1 receptor antagonist [132] Zabaglurant (TMP-301; TMP301; Heptares 25; HTL-0014242; HTL14242) – metabotropic glutamate mGlu5 receptor negative allosteric modulator [133] Zalospirone (WY-47846) – serotonin 5-HT1A receptor agonist [134]
=== From human single-domain antibodies === Humans occasionally produce single domain antibodies by the random creation of a stop codon in the light chain. Human single-domain antibodies targeting various tumor antigens including mesothelin, GPC2 and GPC3 were isolated by phage display. The HN3 human single-domain antibodies have been used to create immunotoxins and chimeric antigen receptor (CAR) T cells for treating liver cancer. Blocking the Wnt binding domain of GPC3 by the HN3 human single-domain antibody inhibits Wnt activation in liver cancer cells.
Sources: en.wikipedia.org
Lenway, Stefanie Ann (1988). "Between war and Commerce: economic sanctions as a tool of statecraft". International Organization. 42 (2). Cambridge University Press: 397–426. doi:10.1017/S0020818300032860. S2CID 154337246. Ong, Andrew (2023). Stalemate: Autonomy and Insurgency on the China-Myanmar Border. Cornell University Press. ISBN 978-1-5017-7071-5. JSTOR 10.7591/j.ctv2t8b78b. Zhang, Chuchu (2025). China's Changing Role in the Middle East: Filling a Power Vacuum?. Changing Dynamics in Asia-Middle East Relations series. Abingdon, Oxon; New York, NY: Routledge. ISBN 978-1-032-76275-3.
In September 2017, Pinnacle Health, a seven-hospital system in South Central Pennsylvania, merged with UPMC and also with Hanover Hospital. Cole Memorial hospital partnered with UPMC Susquehanna and merged with the UPMC system in March 2018. Somerset Hospital, located in Somerset, Pennsylvania, merged with UPMC on February 1, 2019. On February 3, 2020, Western Maryland Health System became the first Maryland hospital to join the UPMC system. Washington Health System merged with UPMC in 2024, resulting in the operation of over 35 academic, community, and specialty hospitals in Pennsylvania, Maryland, and New York, as well as over 600 outpatient sites and doctors' offices, more than 50 facilities for physical, occupational, speech and specialty therapies, and 14 retirement and long-term care site, along with its international and for-profit ventures.
Studies have generally found only very weak inhibition of serotonin and norepinephrine reuptake with trimipramine, and the drug has been described by various authors as devoid of monoamine reuptake inhibition. Richelson & Pfenning (1984) found a relatively high Ki for the NET of 510 nM in rat brain synaptosomes and Tatsumi et al. (1997) found a relatively high KD of 149 nM for the SERT in human HEK293 cells, but other authors and a more recent study with an improved design have not had the same findings. In the most recent study, by Haenisch et al. (2011), the researchers suggested that the discrepant findings from the Tatsumi et al. study were due to methodological differences, in particular the use of radioligand binding in isolated membranes (KD) to study interactions as opposed to actual functional reuptake inhibition (IC50).
A cold chain is a supply chain that uses refrigeration to maintain perishable goods, such as pharmaceuticals, produce or other goods that are temperature-sensitive. Common goods, sometimes called cool cargo, distributed in cold chains include fresh agricultural produce, seafood, frozen food, photographic film, chemicals, and pharmaceutical products. The objective of a cold chain is to preserve the integrity and quality of goods such as pharmaceutical products or perishable goods from production to consumption. A well functioning, or unbroken, cold chain requires uninterrupted sequence of refrigerated production, storage and distribution activities, along with associated equipment and fleet management logistics, which maintain a desired low-temperature interval to keep the safety and quality of perishable or sensitive products. Unlike other goods or merchandise, cold chain goods are perishable and always en-route towards end use or destination. Adequate cold storage, in particular, can be crucial to prevent food loss and waste.
Sources: en.wikipedia.org
Sultan Selim also imported 300,000 bulbs of Kefe Lale (also known as Cafe-Lale, from the medieval name Kaffa, probably Tulipa suaveolens, syn. Tulipa schrenkii) from Kefe in Crimea, for his gardens in the Topkapı Sarayı in Istanbul. It is also reported that shortly after arriving in Constantinople in 1554, Ogier Ghislain de Busbecq, ambassador of the Austrian Habsburgs to the court of Suleyman the Magnificent, claimed to have introduced the tulip to Europe by sending a consignment of bulbs west. The fact that the tulip's first official trip west took it from one court to the other could have contributed to its ascendency. Sultan Ahmet III maintained famous tulip gardens in the summer highland pastures (yayla) at Spil Dağı above the town of Manisa. They seem to have consisted of wild tulips. However, of the 14 tulip species known from Turkey, only four are considered to be of local origin, so wild tulips from Iran and Central Asia may have been brought into Turkey during the Seljuk and especially Ottoman periods. Also, Sultan Ahmet imported domestic tulip bulbs from the Netherlands. The gardening book Revnak'ı Bostan (Beauty of the Garden) by Sahibül Reis ülhaç Ibrahim Ibn ülhaç Mehmet, written in 1660 does not mention the tulip at all, but contains advice on growing hyacinths and lilies. However, there is considerable confusion of terminology, and tulips may have been subsumed under hyacinth, a mistake several European botanists were to perpetuate.
Oxytocin may aid romantically attached couples by increasing feelings of anxiety during separation. Group-serving dishonesty/deception: In a carefully controlled study exploring the biological roots of immoral behavior, oxytocin was shown to promote dishonesty when the outcome favored the group to which an individual belonged instead of just the individual. Oxytocin affects social distance between adult males and females, and may be responsible at least in part for romantic attraction and subsequent monogamous pair bonding. An oxytocin nasal spray caused men in a monogamous relationship, but not single men, to increase the distance between themselves and an attractive woman during a first encounter by 10 to 15 centimeters. The researchers suggested that oxytocin may help promote fidelity within monogamous relationships. For this reason, it is sometimes referred to as the "bonding hormone". There is some evidence that oxytocin promotes ethnocentric behavior, incorporating the trust and empathy of in-groups with their suspicion and rejection of outsiders. Furthermore, genetic differences in the oxytocin receptor gene (OXTR) have been associated with maladaptive social traits such as aggressive behavior. Social behavior and wound healing: Oxytocin is also thought to modulate inflammation by decreasing certain cytokines. Thus, the increased release in oxytocin following positive social interactions has the potential to improve wound healing. A study by Marazziti and colleagues used heterosexual couples to investigate this possibility.
This is evidenced by different projections of AgRP neurons to various areas of the brain driving different food related behaviors; for example, certain projections will promote increased food consumption, but not increased food odor investigation.
Another explanation is that the word hoagie arose in the late 19th to early 20th centuries, among the Italian community in South Philadelphia; at the time "on the hoke" meant that someone was destitute. Deli owners gave away scraps of cheeses and meats in an Italian bread-roll known as a "hokie", but Italian immigrants pronounced it "hoagie". Yet another possible origin of the term, as conveyed by Sociology professor Howard Robboy, is that a man in Philadelphia, Alphonso DePalma, who later opened a sandwich shop there, claimed to have said in 1928, "You have to be a hog to eat one of those." DePalma styled himself as "King of the Hoggies" (and eventually "Hoagies") and at one time had several "hoggie" shops around the city. Shortly after World War II, there were numerous varieties of the term in use throughout Philadelphia. By the 1940s, the spelling "hoagie" dominated less-used variations like "hoogie" and "hoggie". By 1955, restaurants throughout the area were using the term hoagie. Listings in Pittsburgh show hoagies arriving in 1961 and becoming widespread in that city by 1966. Former Philadelphia mayor (and later Pennsylvania governor) Ed Rendell declared the hoagie to be the "Official Sandwich of Philadelphia". However, there are claims that the hoagie was actually a product of nearby Chester, Pennsylvania. DiCostanza's in Boothwyn, Pennsylvania claims that the mother of DiConstanza's owner originated the hoagie in 1925 in Chester.
Some claim that investors like Gilbert are converting Detroit into an oligarchical city whose redevelopment is controlled by only a few powerful figures. Residents have even referred to the downtown area as "Gilbertville" and expressed fears of physical displacement due to the rent increase that results from such investments. Additionally, many long-time residents fear that the influx of new capital could result in their political disempowerment and that the city government will become less responsive to their needs if it is under the influence of outside investors. Other investors, such as John Hantz, are attempting to revitalize Detroit using another approach: urban agriculture. Unlike Gilbert, Hantz has focused on the blighted neighborhoods in Detroit's residential zones. In 2008, Hantz approached Detroit's city government and proposed a plan to remove urban blight by demolishing blighted homes and planting trees to establish a large urban farm. Despite fervent criticisms on behalf of city residents claiming that Hantz's proposal amounted to nothing more than a "land grab", the city government eventually approved Hantz's proposal, granting him nearly 140 acres (57 ha) of land. As of 2017, Hantz Farms has planted over 24,000 saplings and demolished 62 blighted structures. Still, it remains to be seen what Hantz's long-term ambitions are for the project, and many residents speculate future developments on his land. Detroit's resurgence is also being driven by the formation of public-private-nonprofit partnerships that protect and maintain Detroit's most valuable assets.
Sources: en.wikipedia.org
Solutions are best kept cold, protected from light, and buffered to a pH that limits hydrolysis. Dividing a stock into single-use aliquots avoids repeated freeze-thaw cycles, which measurably reduce the intact parent peak over time.
Reversed-phase chromatography establishes a purity profile, while electrospray or matrix-assisted laser desorption mass spectrometry confirms that the observed mass matches the expected sequence. Together they support, but do not fully prove, identity and purity.
Reviews generally characterise it as thin, dominated by small and often uncontrolled studies. Several authors explicitly note that findings on pigmentation, appetite and sexual function have not been confirmed in adequately powered controlled trials.
It is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, containing seven amino acids with a lactam ring and a D-configured phenylalanine residue. It is supplied as a lyophilised powder for laboratory research.